

Do Interleukin-1 β Levels Correlate with MIBG and Exercise Parameters in Heart Failure?

Leandro Rocha Messias, Maria Angela M. de Queiroz Carreira, Sandra Marina Marina Miranda, Jader Cunha de Azevedo, Paula Cardoso Benayon, Ronaldo Campos Rodrigues, Elisabeth Maróstica, Evandro Tinoco Mesquita, Claudio Tinoco Mesquita

Universidade Federal Fluminense, Niterói, RJ – Brazil

Abstract

Background: Interleukin 1 β (IL 1 β) levels are associated with prognosis in heart failure. The cardiac adrenergic activity as assessed by metaiodobenzylguanidine (I^{123} MIBG) scintigraphy along with exercise parameters are important predictors of prognosis. The relationship between these variables is not fully established.

Objective: To evaluate the association of IL 1 β levels with exercise and I^{123} MIBG parameters.

Methods: Cross-sectional observational study evaluating 25 consecutive patients with heart failure and ejection fraction lower than 45% by means of: determination of IL 1 β levels; I^{123} MIBG parameters [early and late heart/mediastinum ratio, washout rate (WO)]; and treadmill exercise test using the ramp protocol.

Results: The patients were divided into two groups according to their IL 1 β levels (normal vs. increased). The group with increased levels showed lower double-product reserve (DPR); lower functional capacity (FC); slower heart rate recovery at the first (HRR 1^o) and second minute (HRR 2^o); and higher WO. In the univariate analysis, all variables correlated with IL 1 β ; DPR: $r = 0.203$, $p = 0.024$; FC: $r = 0.181$, $p = 0.034$; HRR 1^o: $r = 0.182$, $p = 0.034$; HRR 2^o: $r = 0.204$, $p = 0.023$; WO: $r = 0.263$, $p = 0.009$. In the multivariate analysis, only WO maintained a significant correlation ($r^2 = 0.263$, $p = 0.009$).

Conclusion: Adrenergic overactivity was the main determinant of IL 1 β levels, thus demonstrating that an excessive sympathetic activity influences the systemic inflammatory response. Exercise test variables were not able to identify patients with high IL 1 β levels. (Arq Bras Cardiol. 2013; [online].ahead print, PP.0-0)

Keywords: Interleukin-1beta Heart Failure; Exercise; 3-Iodobenzylguanidine.

Introduction

Heart failure (HF) is an inflammatory neuroendocrine syndrome associated with worsening of the functional capacity, decreased quality of life, and increased morbidity and mortality^{1,2}. In this syndrome, there is a renin-angiotensin-aldosterone axis activation and adrenergic overstimulation, thus configuring a neurohumoral imbalance² which is directly related to left ventricular dysfunction, regardless of the functional class³, and is correlated with a worse prognosis⁴.

The cardiac activity and sympathetic innervation may be evaluated by iodine 123 metaiodobenzylguanidine scintigraphy (I^{123} MIBG)^{5,6}. The early imaging represents the presynaptic nerve ending integrity and beta-receptors

density. Presynaptic neuronal uptake contributes to the late imaging, combining information on the neural function including norepinephrine uptake, release and storage in the presynaptic vesicles. The washout rate is a parameter which assesses the degree of sympathetic activity⁶. Patients with HF may present with: reduced radiotracer uptake due to the loss of sympathetic neurons and/or primary norepinephrine uptake disturbances; and increased washout rate reflecting norepinephrine overflow to the blood stream^{5,7}.

In HF, peripheral and intracardiac levels of inflammatory cytokines are elevated, and the increase in their serum levels is proportional to the clinical deterioration and severity of the disease, also contributing to endothelial dysfunction, oxidative stress, anemia, pulmonary edema, and loss of muscle mass⁸⁻¹⁰. Among the cytokines which are elevated in HF is interleukin 1 β (IL 1 β), which depresses cardiac contraction and is involved in myocardial apoptosis, hypertrophy and arrhythmogenesis^{9,11}.

The indications for an exercise test in HF include evaluation of the presence of symptoms and treatment; detection of the presence of ischemia; and determination

Mailing Address: Leandro Rocha Messias •

Rua Noronha Torreção, 46 - Apto 805, Santa Rosa, Postal Code 24240-182, Niterói, RJ – Brazil

E-mail: lmessias@cardiol.br, leandromess@gmail.com

Manuscript received April 12, 2012, revised manuscript October 06, 2012, accepted November 27, 2012.

DOI: 10.5935/abc.20130056

of the functional capacity¹². The functional capacity and heart rate recovery (HRR) in the post-exertion period are some of the parameters assessed that are known to be predictive of prognosis^{13,14}.

To date, it is not clear whether IL 1 β correlates with adrenergic innervation and/or exercise parameters. Therefore, the objective of our study is to evaluate the association of IL 1 β levels with exercise test and I¹²³ MIBG scintigraphy parameters in patients with HF and reduced ejection fraction.

Methods

A cross-sectional observational study of 25 consecutive patients seen in the HF outpatient clinic was conducted. The patients selected showed a left ventricular ejection fraction equal to or lower than 45% as measured by echocardiography using Simpson's technique. Patients presenting with atrial fibrillation, diabetes, ventricular pacing device, endocrine diseases, Parkinson's disease, cold, chronic inflammatory diseases, as well as pregnant women or those who were breastfeeding were excluded from the study.

Patients with New York Heart Association (NYHA) functional classes I and II were selected for observation of the inflammatory and adrenergic profiles in their group and, consequently, for observation of whether these parameters would influence exercise variables. All patients were being treated with optimized doses of standard medications for HF, and no medication was discontinued for the study to be conducted. Volunteers gave written informed consent to participate in the study. The project was approved by the Institutional Research Ethics Committee, under number 011/09

The following criteria were used for the classification of the cause of HF: ischemic (covering history of acute myocardial infarction; presence of an inactive area on electrocardiogram or coronary angiography showing left main coronary artery lesion equal to or greater than 50%, or lesion equal to or greater than 70% in one of the three main systems – anterior descending, circumflex and right coronary)¹⁵; hypertensive (covering history of hypertension and absence of criteria for ischemic etiology); and other (covering patients not classified as having ischemic or hypertensive etiology, for instance: idiopathic dilated cardiomyopathy, post-myocarditis, *peripartum*).

For patients to undergo I¹²³ MIBG myocardial scintigraphy, they had to be previously prepared for thyroid protection with 10 mL of oral potassium iodide administered 48 h prior to the imaging test. On the day of the test, the patients were instructed not to take any caffeine-containing beverages (coffee, black tea, sodas, chocolate), and to remain fasted for two hours. Planar images were obtained using a 5 mCi dose of I¹²³-labelled MIBG. The semiquantitative measure of I¹²³ MIBG myocardial uptake was obtained by calculating the heart/mediastinum ratio (H/M) for early imaging (30 minutes after radiotracer injection) and the late imaging (4 hours after injection), in addition to the calculation of the washout rate using the formula $\{(H/M \text{ early} - H/M \text{ late}) / (H/M \text{ early}) \times 100\}$ ⁵.

All tests were carried out in a Siemens, E-Cam double detector model, with low-energy collimator and high-resolution Anger digital tomographic scintillation chamber (Single Photon Emission Computed Tomography).

Medications used for the treatment of heart failure were not discontinued and none of the study patients was on other medication, such as tricyclic antidepressants, reserpine, guanethidine, phenylephrine, pseudoephedrine, phenylpropranolamine, antipsychotic drugs, or calcium-channel blockers, which could influence the I¹²³ MIBG results.

On the day of the exercise test, the patients were instructed not to drink any caffeine-containing beverages, not to smoke, to eat a light meal at most three hours prior to the test (they should not be fasting), not to practice extenuating physical exercises, not to drink alcoholic beverages on the day before and on the day of the test, and to keep taking their regular medications. Two tests were performed. The exercise test was symptom-limited (software program ErgoPC 13 version 2.2), in an Imbramed treadmill duly calibrated according to the manufacturer's instructions. The first test was performed using the Naughton's protocol in order to train the patients and better adapt them to the treadmill.

After a 7 to 10-day interval, the second test was performed using the customized ramp protocol, starting at a speed of 1.6 km/h, with no inclination. Speed and inclination were programmed so that the VO₂ estimated in the first test would be achieved in 10 minutes in the second test. No patient performed the test in less than 8 minutes of exercise. The study variables were obtained in the second test.

Behavior of blood pressure during exercise, of heart rate during exercise and recovery, and the estimated functional capacity were evaluated. Heart rate was measured using the RR interval in the ECG tracing with the software program itself. Blood pressure was measured using the indirect method with a mercury-column sphygmomanometer duly calibrated, placed on the left arm of the patients in the standing position. Functional capacity was estimated by the software program by means of the number of METs reached. The modified BORG scale¹⁶ was used to determine the peak exercise, and only patients who completed the test for maximum exhaustion (BORG 10) participated in the study.

The recovery protocol was the same for all patients: 2 minutes in active recovery (speed 1.6 km/h; no inclination) and 4 minutes in passive recovery in the standing position on the treadmill. The heart rate recovery (HRR) value was determined by subtracting the absolute heart rate value at the peak exercise from the absolute heart rate value in the first and second minutes of recovery.

Prior to the exercise test, a blood sample was collected by right antecubital venipuncture after applying a tourniquet on the right arm. After proper aseptic technique with alcohol 70% to clean the puncture site, 10 mL of blood were collected by means of a 20-mL syringe and 25x8 needle and distributed into two tubes containing EDTA. The sample was centrifuged at 100 rpm, and the plasma was separated from the cells; the plasma IL 1 β level was then determined. The Quantikine immunoassay kit (R&D Systems, Inc, Minneapolis, USA) consisting of a solid-phase ELISA with 3.5 – 4.5 h duration was

used. This is a quantitative sandwich immunoassay and the determinations were made according to the manufacturer's recommendations. The normal reference value used was lower than 4.0 pg/mL.

The SPSS version 15 was used for the statistical analysis. Values were expressed as percentage, median and interquartile range. The chi square test was used for the analysis of qualitative variables. The Mann-Whitney U test was used for the analysis of quantitative variables because of the non-parametric data distribution. Univariate and multivariate analyses were used to study the correlation between the variables analyzed and IL 1 β . The level of statistical significance was set at $p < 0.05$.

Results

The patients were evaluated according to their degree of inflammatory activity, and the sample was divided into two groups: Group 1 (G1): IL 1 β < 4.0 pg/mL (no inflammation); and Group 2 (G2): IL 1 β \geq 4.0 pg/mL (with inflammation). The overall characteristics of the groups are shown in Table 1. No significant differences were observed as regards age, gender, body mass index, presence of hypertension, dyslipidemia, smoking habit, and ventricular ejection fraction. The etiology of HF in most of the patients of our sample was hypertension: Group 1, 7 patients (70%), and Group 2, 10 patients (66.7%). The etiology of HF in the remaining patients of Group 1 was: one patient (10%) had ischemic HF and two (20%) were classified as having non-ischemic, non-hypertensive HF; one of these was peripartum and the other, idiopathic. In Group 2, two patients (13.3%) had ischemic HF, whereas three (20%) had HF of other causes (one peripartum and two idiopathic). No significant differences were observed regarding the etiology of HF, medications used, or NYHA functional class.

As regards the scintigraphy parameters, no significant difference was observed in the early heart/mediastinum ratio (H/M) (G1: 1.76 (1.48 – 1.96) vs. G2: 1.76 (1.64 – 1.99), $p = 0.579$) or late H/M ratio (G1: 1.76 (1.48 – 1.96) vs. G2: 1.65 (1.5 – 1.83), $p = 0.437$). However, there was a significant difference regarding the washout rate (G1: 20.5% (12 – 26.1) vs. G2: 31% (23.5 – 36.3), $p = 0.003$), thus demonstrating that the group of patients with the worst inflammatory profile also showed an adrenergic overactivity status at rest.

During the exercise test, Group 2 showed lower intra-exercise systolic blood pressure variation, lower double-product reserve, lower functional capacity, and slower HRR at the 1^o and 2^o minutes, as shown in Table 2.

Since we considered that other variables could influence the results, uni and multivariate analyses were carried out to determine which variables were more correlated with IL 1 β (dependent variable). Table 3 shows that in the univariate analysis, the I¹²³ MIBG washout rate, double-product reserve, functional capacity and 1^o and 2^o minute HRR were variables associated with IL 1 β ; in the multivariate analysis, the I¹²³ MIBG washout rate was the only variable that really correlated with serum IL 1 β levels.

Graph 1 shows the correlation between IL 1 β and the I¹²³ MIBG washout rate.

Discussion

After multivariate analysis, we observed that IL 1 β correlated with the I¹²³ MIBG washout rate (an adrenergic overactivity marker). We can presume that the resting adrenergic activity influenced the serum levels of this marker. Thus, I¹²³ MIBG myocardial scintigraphy was superior to conventional exercise test in the detection of patients with HF and a worse inflammatory profile.

There are several hypotheses to explain the pathophysiological mechanism of increased cytokines in HF. The central mechanism hypothesis proposes that an event, whether acute or chronic, such as myocardial ischemia, which results in a decrease in cardiac output and/or increase in filling pressures, would lead to increased ventricular wall stress, thus activating intraventricular baroreceptors and stimulating the sympathetic activity¹⁷. This increased cardiac sympathetic activity associated with myocardial lesion would be the triggering factor for the myocardial production of cytokines¹⁸. Once produced, these cytokines will activate local monocytes and macrophages, thus triggering the local inflammatory process. Later, the cytokines are released in the bloodstream, activating peripheral monocytes and macrophages and increasing the local production of these substances. In addition to stimulating the cardiac production of cytokines again, this systemic elevation also depresses the myocardial function. By a direct (acting on the central control base) or indirect (myocardial depression) mechanism, it will perpetuate the hyperadrenergic status characteristic of heart failure, which is also a stimulating factor for the inflammatory response, thus generating a positive feedback vicious cycle¹⁹.

We believe this is the pathophysiological mechanism that accounts for the correlation between the I¹²³ MIBG washout rate and IL 1 β demonstrated in our study.

Another hypothesis to explain the inflammatory activity in HF is the peripheral mechanism, in which, as a result of the low cardiac output, the hypoperfused muscle would activate cytokine production by peripheral monocytes, thus leading to more depression of the ventricular function, and further worsening of the peripheral perfusion¹⁹. Lastly, the intestinal mechanism hypothesis: mesenteric hypoxia associated with intestinal loop edema would lead to translocation of bacteria and/or their endotoxins from the bowel into the bloodstream, thus activating and perpetuating the systemic inflammatory response²⁰.

In the heart, IL 1 β causes a dose-dependent depression of myocardial contractility and is involved in myocardial apoptosis, myocyte hypertrophy, and arrhythmogenesis^{9,18}. After an acute myocardial infarction episode, IL 1 β regulates the inflammatory response and is one of the factors responsible for ventricular remodeling²¹.

In a recently completed study analyzing patients with ST-segment elevation acute myocardial infarction, Abbate et al²² observed favorable effects of IL 1 β receptor blockade with anakinra, administered for 14 days, on ventricular remodeling observed at 90 days after infarction. Van Tassel et al²³ demonstrated that increased IL 1 β levels in patients with HF contributed to worse exercise tolerance, and IL 1 β receptor blockade by means of anakinra improved peak oxygen consumption (VO₂ peak) with better ventilatory efficiency, as assessed by the VE/CO₂ slope. In our study, we could observe that patients with increased IL 1 β levels also showed poorer functional capacity.

Table 1 - Comparison of groups divided according to IL 1 β values

Variable	G1 (normal) IL 1 β < 4.0 pg/ml	G2 (with inflammation) IL 1 β \geq 4.0 pg/ml	P
N	10	15	
Age (years)	52.5 (44 – 58.75)	60 (45 – 66)	0,255
Gender (F/M)	5/5	4/11	0,243
BMI (Kg/m ²)	26 (24.05 – 28.97)	27.47 (23.6 – 32.8)	0,739
SAH	80%	80%	0,996
Dyslipidemia	50%	60%	0,629
Smoking habit	30%	20%	0,574
Etiology			0,886
Ischemic	10%	13.3%	
Hypertensive	70%	66.7%	
Other	20%	20%	
LVEF (%)	34 (29.75 – 44.25)	36 (29 – 39)	0,358
Betablocker	100%	100%	1
ACEI/ARA II	60%	73.3%	0,667
Spirolactone	100%	93.3%	0,414
Diuretics	90%	93.3%	0,768
Digitalis	50%	46.7%	0,873
Hydralazine	20%	0	0,077
Nitrate	20%	6.7%	0,325
ASA	20%	26.7%	0,708
Statin	50%	60%	0,629
NYHA			0,607
I	70%	66.7%	
II	30%	33.3%	
IL 1 β	0.87 (0.72 – 3.57)	4.64 (4.35 – 5.14)	0,0001

Numerical variables are expressed as median and interquartile range; categorical variables, as number or percentage. G1: group 1; G2: group 2; IL 1 β : interleukin 1 beta; pg/mL: picograms per milliliters; N: number; F: female gender; M: male gender; BMI: body mass index; Kg/m²: kilogram per square meter; SAH: systemic arterial hypertension; LVEF: left ventricular ejection fraction; ACEI: angiotensin II converting enzyme inhibitor; ARA II: angiotensin II receptor antagonist; ASA: acetylsalicylic acid; NYHA: New York Heart Association functional class.

The washout rate is considered a sympathetic activity marker, so that sympathetic overactivity is characterized by high washout and low I¹²³ MIBG myocardial uptake²⁴, which could more accurately reflect the catecholamine kinetics attributed to the adrenergic activity, because it is independent of the amount of adrenergic neurons, measuring the myocardial MIBG reuptake ability²⁵.

Ogita et al²⁶ studied the prognostic power of the washout rate to predict morbidity and mortality in patients with heart failure. The 27% value was a good predictor of prognosis, because the group of patients with values above this cut-off point showed higher mortality rates, higher hospital readmission rates, and clinical worsening of HF. Carrió et al²⁷ also demonstrated that patients with a washout rate higher than 27% showed higher rates of sudden death. In our study, we found that patients of the group with inflammation had washout rates higher than 27%, thus corroborating the

findings described^{26,27}; this group has a higher probability of the occurrence of adverse events. In the ADMIRE-HF study²⁸, the washout rate was also associated with an increased risk of cardiac events; however, it was not superior to the late heart/mediastinum (H/M) ratio.

According to Patrianakos et al's study²⁹, the levels of inflammatory cytokines, including IL 1 β , were increased in patients with dilated cardiomyopathy and diastolic dysfunction (restrictive pattern), and was associated with a decreased functional capacity. The authors concluded that the diastolic dysfunction may contribute to the increase in cytokine levels and to the reduction of the functional capacity. In our study, we did not evaluate the diastolic function; however, the group of patients with a worse inflammatory profile was also the group with a worse estimated functional capacity. Parthenakis et al³⁰ studied patients with HF and demonstrated that increased serum levels of inflammatory cytokines are related to reduced

Table 2 - Comparison of groups, as divided by IL 1 β levels, during the exercise test


Variable	G1 (normal) IL 1 β < 4.0 pg/ml	G2 (with inflammation) IL 1 β \geq 4.0 pg/ml	P
SBP BE (mmHg)	114 (103.5 – 131.5)	122 (96 -132)	0.637
DBP BE (mmHg)	79 (72 – 90.5)	78 (70 – 82)	0.241
HR BE (bpm)	73 (70 – 75.75)	76 (68 – 83)	0.636
SBP P (mmHg)	172 (154 – 207)	160 (140 – 188)	0.202
HR P (bpm)	135 (122.5 – 150)	122 (107 – 137)	0.149
SBP PIN (mmHg)	61 (43.5 – 71)	42 (32 – 58)	0.04
CRI (%)	62.4 (55.57 – 80.67)	56.38 (45.45 – 73.86)	0.12
DP max (mmHg.bpm)	26361 (18201-28212)	18800 (16940-24320)	0.096
DPR (mmHg.bpm)	17908 (11106-18942)	10570 (7854-14744)	0.015
FC (METs)	8.23 (5.85 – 9.53)	5.95 (3.32 – 7.55)	0.035
HRR 1 min (bpm)	21.5 (17 – 28.5)	11 (7 – 19)	0.019
HRR 2 min (bpm)	31 (28.5 – 37.75)	21 (12 – 35)	0.028

SBP BE: systolic blood pressure prior to the beginning of the test; mmHg: millimeters of mercury; DBP BE: diastolic blood pressure prior to the beginning of the test; HR BE: heart rate before the beginning of the test; bpm: beats per minute; SBP P: systolic blood pressure at peak exercise; HR P: heart rate at peak exercise; CRI: chronotropic reserve index; DP: double product; max: maximum; DPR: double product reserve; FC: functional capacity; HRR 1: heart rate recovery at the first minute of recovery in comparison to peak exercise; min: minute; HRR 2: heart rate recovery at the second minute of recovery in comparison to peak exercise.

Table 3 - Uni and multivariate analyses of the variables analyzed using IL 1 β as a dependent variable

Analysis	Univariate r	p	Multivariate r ² : 0.263	p
Age	0.033	0.384		0.201
Gender	0.057	0.252		0.227
BMI	0.023	0.469		0.094
Dyslipidemia	0.01	0.639		0.36
Smoking habit	0.013	0.585		0.277
Etiology	0.001	0.890		0.311
LVEF	0.045	0.311		0.83
ACEI/ARA II	0.02	0.504		0.255
Spironolactone	0.028	0.426		0.199
ASA	0.006	0.716		0.288
Statin	0.021	0.488		0.223
Early H/M	0.013	0.593		0.564
Late C/M	0.032	0.39		0.843
WO	0.263	0.009		0.009
SBP PIN BE	0.139	0.066		0.562
DP reserve	0.203	0.024		0.212
FC	0.181	0.034		0.335
HRR 1 min	0.182	0.034		0.228
HRR 2 min	0.204	0.023		0.211

BMI: body mass index; LVEF: left ventricular ejection fraction; ACEI: angiotensin II converting enzyme inhibitor; ARA II: angiotensin II receptor antagonist; ASA: acetylsalicylic acid; H/M: heart mediastinum ratio; WO: washout rate; SBP PIN BE: systolic blood pressure before the beginning of the test; DP: double product; FC: functional capacity; HRR 1: heart rate recovery at the first minute of recovery in comparison to peak exercise; min: minute; HRR 2: heart rate recovery at the second minute of recovery in comparison to peak exercise.



Graph 1: Graph of the correlation between interleukin 1 β and I¹²³ MIBG washout rate. IL 1: interleukin 1 β ; WO: washout rate.

cardiac sympathetic innervation. The authors demonstrated that there was a relationship between myocardial I¹²³ MIBG uptake, tumoral necrosis factor α (TNF- α), IL 1 β , parameters of the left ventricular function, and VO₂ peak. They concluded that changes in the cardiac sympathetic innervation have a significant correlation with cytokine levels, thus corroborating the hypothesis that an abnormal cardiac adrenergic activity and its cardiovascular consequences lead to a loss of the inhibitory effect on the production of inflammatory cytokines, which contributes to the elevation of their plasma levels.

Turpeinen et al⁵ studied another HF cohort and analyzed the correlation between changes in the cardiac sympathetic innervation, inflammation and neurohumoral activity. The authors concluded that changes in the cardiac adrenergic innervation would lead to increased cytokine levels, which, in turn, would contribute to perpetuate the cardiac autonomic dysfunction. In our study, we demonstrated that there is an association between the washout rate and IL 1 β (multivariate analysis), IL 1 β and heart rate recovery (HRR) at the 1st and 2nd minutes post-exercise (univariate analysis), which leads us to assume that the adrenergic overactivity at rest was the factor that contributed to the post-exercise parasympathetic dysfunction, as has already been demonstrated in another study³¹.

Our research team³² evaluated the relationship between the washout rate and conventional exercise test variables in patients with HF and reduced ejection fraction and demonstrated that the group of patients with increased washout rate showed a lower inotropic and chronotropic response during exercise, as well as a lower functional capacity. In the linear regression analysis, systolic blood pressure at peak exercise and functional capacity in METs were the variables that best correlated with the washout rate.

This association between adrenergic activity and inflammation has also been described in other diseases, as was demonstrated in Diakakis et al's study³³, in which the authors evaluated patients with glucose intolerance and demonstrated that an abnormal cardiac sympathetic innervation and increased adrenergic activity are correlated with a worse inflammatory profile, and can be considered an early atherosclerosis marker. Shinohara et al³⁴ evaluated diabetic patients and described the association of high IL6 levels with impaired late heart/mediastinum ratio and increased I¹²³ MIBG washout rate. The authors reported that the mechanism responsible for the adrenergic overactivity related to increased IL6 levels is the β_2 -adrenergic stimulation and the increased insulin resistance. Insulin resistance is one of the factors responsible for autonomic neuropathy in type-2 diabetes. Thus, β_2 -adrenergic stimulation would lead to sympathetic overactivity, with increased IL6 levels, and the elevation of this cytokine, in turn, would worsen insulin resistance and result in more cardiac autonomic dysfunction³⁴.

The variables studied during the exercise test were not able to identify our heart failure cohort with a worse inflammatory profile. After multivariate analysis, we verified that the main factor that influenced our findings was the I¹²³ MIBG washout rate. The double product reserve, estimated functional capacity, and 1st and 2nd HRR were associated with IL 1 β ; however, in previous studies^{31,32}, we had already demonstrated that the washout rate is correlated with these variables. We did not evaluate the intra-exercise RR variability variable, which assesses the action of both components of the autonomic nervous system in the sinus node³⁵. However, it has already been reported that there is a correlation between washout rate and RR variability³⁶.

We believe that HF is a severe, complex syndrome, and that further understanding of its pathophysiology is fundamental for an improved therapeutic approach. In the search for risk markers, I^{123} MIBG myocardial scintigraphy has emerged as a relatively new, not frequently used method, but it is quite useful in the risk stratification of these patients. The association of its parameters with inflammatory markers and exercise parameters shows the importance of the autonomic nervous system in the pathophysiology of HF.

Study limitations

The main study limitation was the small number of patients. However, by means of a pilot study of 16 patients, a sample calculation was carried out and the total number of 10 patients per group would be necessary to identify a 33.8% difference between the washout rate means for and α error of 5% and a β error of 80%.

Another limitation was the impossibility to perform a cardiopulmonary exercise test (CPET) to ensure that the patients had performed the maximum test. However, as previously described, only patients who completed the test for exhaustion (score 10 in the perceived tiredness scale of modified BORG) participated in the study. We are aware of the fact that the estimated functional capacity has a large error margin; nonetheless, we believe that it is an important parameter in the assessment of patients with HF, because it is directly correlated with VO_2 peak³⁷ and I^{123} MIBG parameters³¹.

CPET was not performed because the equipment was not available in our institution at the time the present study was conducted. However, blood pressure and heart rate may be assessed by conventional exercise test without requiring complex methodology for analysis.

Conclusion

The adrenergic overactivity status, as diagnosed by the I^{123} MIBG washout rate, was the main determinant of IL 1 β levels, thus demonstrating that an excessive sympathetic activity has an influence on the systemic inflammatory activity, and inflammation also has an effect on the cardiac autonomic dysfunction. The exercise test variables were not able to identify patients with high IL 1 β levels.

Potential Conflict of Interest

No potential conflict of interest relevant to this article was reported.

Sources of Funding

This study was partially funded by FAPERJ e CNPq.

Study Association

This article is part of the thesis of doctoral submitted by Leandro Rocha Messias, from Universidade Federal Fluminense.

References

1. Bacal F, Souza-Neto JD, Fiorelli AI, Mejia J, Marcondes-Braga FG, Mangini S, et al; Sociedade Brasileira de Cardiologia. II Diretriz brasileira de transplante cardíaco. *Arq Bras Cardiol*. 2009;94(1 supl.1):e16-e73.
2. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of left Ventricular Dysfunction (SOLVD). *Circulation*. 1990;82(5):1724-9.
3. Benedict CR, Johnstone DE, Weiner DH, Bourassa MG, Bittner V, Kay R, et al. Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the Registry of Studies of Left Ventricular Dysfunction. SOLVD Investigators. *J Am Coll Cardiol*. 1994;23(6):1410-20.
4. Swedberg K, Eneroth P, Kjeksus J, Wilhelmssen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. *Circulation*. 1990;82(5):1730-6.
5. Turpeinen AK, Vanninen E, Magga J, Tuomainen P, Kuusisto J, Sipola P, et al. Cardiac sympathetic activity is associated with inflammation and neurohumoral activation in patients with idiopathic dilated cardiomyopathy. *Clin Physiol Funct Imaging*. 2009;29(6):414-9.
6. Agostini D, Carrio I, Verberne HJ. How to use myocardial ^{123}I -MIBG scintigraphy in chronic heart failure. *Eur J Nucl Med Mol Imaging*. 2009;36(4):555-9.
7. Ji SY, Travin MI. Radionuclide imaging of cardiac autonomic innervation. *J Nucl Cardiol*. 2010;17(4):655-66.
8. Maeda K, Tsutamoto T, Wada A, Mabuchi N, Hayashi M, Tsutsui T, et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. *J Am Coll Cardiol*. 2000;36(5):1587-93.
9. Von Haehling S, Schefold JC, Lainscak M, Doehner W, Anker SD. Inflammatory biomarkers in heart failure revisited: much more than innocent bystanders. *Heart Fail Clin*. 2009;5(4):549-60.
10. Heymans S, Hirsch E, Anker SD, Aukrust P, Balligand JL, Cohen-Tervaert JW, et al. Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail*. 2009;11(2):119-29.
11. Candia AM, Villacorta H Jr, Mesquita ET. Ativação imune-inflamatória na insuficiência cardíaca. *Arq Bras Cardiol*. 2007;89(3):183-90, 201-8.
12. Meneghelo RS, Araújo CG, Stein R, Mastrocolla LE, Albuquerque PF, Serra SM, et al; Sociedade Brasileira de Cardiologia. III Diretrizes da Sociedade Brasileira de Cardiologia sobre teste ergométrico. *Arq Bras Cardiol*. 2010;95(5 supl.1):1-26.
13. Snader CE, Marwick TH, Pashkow FJ, Harvey SA, Thomas JD, Lauer MS. Importance of estimated functional capacity as a predictor of all-cause mortality among patients referred for exercise thallium single-photon emission computed tomography: report of 3,400 patients from a single center. *J Am Coll Cardiol*. 1997;30(3):641-8.
14. Arena R, Myers J, Abella J, Peberdy MA, Bensimhon D, Chase P, et al. The prognostic value of the heart rate response during exercise and recovery in patients with heart failure: influence of beta-blockade. *Int J Cardiol*. 2010;138(2):166-73.

15. Scanlon PJ, Faxon DP, Audet AM, Carabello B, Dehmer GJ, Eagle KA, et al. ACC/AHA Guideline for coronary angiography. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on Coronary Angiography). Developed in collaboration with the Society for Cardiac Angiography and Interventions. *J Am Coll Cardiol.* 1999;33(6):1756-824.
16. Wilson RC, Jones PW. A comparison of the visual analogue scale and modified BORG scale for the measurement of dyspnoea during exercise. *Clin Sci (Lond).* 1989;76(3):277-82.
17. Floras JS. Sympathetic nervous system activation in human heart failure: clinical implications of an updated model. *J Am Coll Cardiol.* 2009;54(5):375-85.
18. Anker SD, Von Haehling S. Inflammatory mediators in chronic heart failure: an overview. *Heart.* 2004;90(4):464-70.
19. Braunwald E. Biomarkers in heart failure. *N Engl J Med.* 2008;358(20):2148-59.
20. Peschel T, Schonauer M, Thiele H, Anker SD, Schuler G, Niebauer J. Invasive assessment of bacterial endotoxin and inflammatory cytokines in patients with acute heart failure. *Eur J Heart Fail.* 2003;5(5):609-14.
21. Han RO, Ray PE, Baughman KL, Feldman AM. Detection of interleukin and interleukin-receptor mRNA in human heart by polymerase chain reaction. *Biochem Biophys Res Commun.* 1991;181(2):520-3.
22. Abbate A, Kontos MG, Grizzard JD, Biondi-Zoccai GG, Van Tassell BW, Robati R, et al; VCU-ART Investigators. Interleukin 1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction. (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). *Am J Cardiol.* 2010;105(10):1371-7.
23. Van Tassell BW, Arena RA, Toldo S, Mezzaroma E, Azam T, Seropian IM, et al. Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure. *PLoS One.* 2012;7(3):e33438.
24. Verberne HJ, Brewster LM, Somsen A, van Eck-Smit BL. Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systematic review. *Eur Heart J.* 2008;29(9):1147-59.
25. Yuama R, Yuasa F, Hikosaka M, Mimura J, Kawamura A, Hatada K, et al. Iodine 123-metaiodobenzylguanidine imaging reflect generalized sympathetic activation in patients with left ventricular dysfunction. *Clin Physiol Funct Imaging.* 2005;25(1):34-9.
26. Ogita H, Shimonagata T, Fukunami M, Kumagai K, Yamada T, Asano Y, et al. Prognostic significance of cardiac ¹²³I metaiodobenzylguanidine imaging for mortality and morbidity in patients with chronic heart failure: a prospective study. *Heart.* 2001;86(6):656-60.
27. Carrió I, Cowie MC, Yamazaki J, Udelson J, Camici PG. Cardiac sympathetic imaging with MIBG in heart failure. *JACC Cardiovasc Imaging.* 2010;3(1):92-100.
28. Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA, et al; ADMIRE-HF Investigators. Myocardial Iodine-123 Meta-Iodobenzylguanidine Imaging and Cardiac Events in Heart Failure. Results of the prospective ADMIRE-HF Study. *J Am Coll Cardiol.* 2010;55(20):2212-21.
29. Patrianakos AP, Parthenakis FI, Papadimitriou EA, Diakakis GF, Tzerakis PG, Nikitovic D, et al. Restrictive filling pattern is associated with increased humoral activation and impaired exercise capacity in dilated cardiomyopathy. *Eur J Heart Fail.* 2004;6(6):735-43.
30. Parthenakis FI, Patrianakos A, Prassopoulos V, Papadimitriou E, Nikitovic D, Karkavitsas NS, et al. Relation of cardiac sympathetic innervation to proinflammatory cytokine levels in patients with heart failure secondary to idiopathic dilated cardiomyopathy. *J Am Coll Cardiol.* 2003;91(10):1190-4.
31. Messias LR, de Queiroz Carreira MA, Miranda SM, de Azevedo JC, Gava IA, Rodrigues RC, et al. Ativação adrenérgica alterada se associa à recuperação anormal da frequência cardíaca? *Arq Bras Cardiol.* 2012;98(5):398-405.
32. Messias LR, Carreira MA, Miranda SM, Azevedo JC, Gava IA, Rodrigues RC, et al. Relação entre imagem adrenérgica cardíaca e teste ergométrico na insuficiência cardíaca. *Arq Bras Cardiol.* 2011;96(5):370-6.
33. Diakakis GF, Parthenakis FI, Patrianakos AP, Koukouraki SI, Stathaki MI, Karkavitsas NS, et al. Myocardial sympathetic innervation in patients with impaired glucose tolerance: relationship to subclinical inflammation. *Cardiovasc Pathol.* 2008;17(3):172-7.
34. Shinohara T, Takahashi N, Yufu K, Anan F, Kakuma T, Hara M, et al. Role of interleukin-6 levels in cardiovascular autonomic dysfunction in type 2 diabetic patients. *Eur J Nucl Med Mol Imaging.* 2008;35(9):1616-23.
35. Freeman JV, Dewey FE, Hadley DM, Myers J, Froelicher VF. Autonomic Nervous system interaction with the cardiovascular system during exercise. *Prog Cardiovasc Dis.* 2006;48(5):342-62.
36. Simula S, Vanninen E, Hedman A, Lehto S, Kuikka J, Hartikainen J. Myocardial 123I-metaiodobenzylguanidine washout and heart rate variability in asymptomatic subjects. *Ann Noninvasive Electrocardiol.* 2012;17(1):8-13.
37. Myers J, Zaheer N, Quaglietti S, Madhavan R, Froelicher V, Heidenreich P. Association of functional and health status measures in heart failure. *J Card Fail.* 2006;12(6):439-45.

